Biotech · Private company
Carmot Therapeutics, Inc.
Track this companyFree. Adds Carmot Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- CT-868Phase 2 · OverweightClinicalTrials.gov · fetched Nov 12, 2026
- CT-868 Pen InjectorPhase 2 · OverweightClinicalTrials.gov · fetched Nov 12, 2026
- EnicepatidePhase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- EnicepatidePhase 2 · Overweight or ObeseClinicalTrials.gov · fetched Nov 12, 2026
- Active Comparator as SC InjectionPhase 1 · DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- CT-868Phase 1 · Type 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- CT-868 as SC InjectionPhase 1 · DiabetesClinicalTrials.gov · fetched Nov 12, 2026
- VictozaPhase 1 · Type 1 DiabetesClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusPHASE2 · COMPLETED · started Nov 21, 2024ClinicalTrials.gov NCT06628362 · fetched Nov 12, 2026
- A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityPHASE2 · COMPLETED · started Aug 16, 2024ClinicalTrials.gov NCT06525935 · fetched Nov 12, 2026
- A Study of CT-868 in Type 1 Diabetes MellitusPHASE2 · COMPLETED · started Nov 27, 2023ClinicalTrials.gov NCT06062069 · fetched Nov 12, 2026
- A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesPHASE1 · COMPLETED · started Mar 21, 2023ClinicalTrials.gov NCT05794581 · fetched Nov 12, 2026
- A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood GlucosePHASE1 · COMPLETED · started Jul 16, 2021ClinicalTrials.gov NCT04973111 · fetched Nov 12, 2026